Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori Eradication

Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori Eradication - Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022963

Enrollment

100

Registered

2016-07-10

Start date

2016-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection

Interventions

Triple therapy with Vonoprazan, amoxicillin and clatrithromycin Dual therapy with vonoprazan and amoxicillin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients infected with H. pylori Patients not allergic to any of drugs used in the eradication therapy Patients from whom IC has been obtained

Exclusion criteria

Exclusion criteria: Patients uninfected with H. pylori Patients who have ever failed in eradication more than two times. Patients from whom IC cannot be obtained Patients considered not eligible to the study

Design outcomes

Primary

Measure	Time frame
eradication rate of H. pylori Success or failure of eradication is assessed by thr 13C-urea breath test at 4 - 8 weeks after the eradication therapy	—

Secondary

Measure	Time frame
Adverse events	—

Countries

Japan

Contacts

Public ContactTakahisa Furuta

Hamamatsu University School of Medicine Center for Clinical Research

furuta@hama-med.ac.jp053-435-2850

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026